CHINA PHARMA HOLDINGS INC (CPHI)
US16941T3023 - Common Stock
We assign a fundamental rating of 1 out of 10 to CPHI. CPHI was compared to 193 industry peers in the Pharmaceuticals industry. CPHI has a bad profitability rating. Also its financial health evaluation is rather negative. CPHI does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
CPHI had negative earnings in the past year.
CPHI had a positive operating cash flow in the past year.
In the past 5 years CPHI always reported negative net income.
In the past 5 years CPHI reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of CPHI (-30.88%) is comparable to the rest of the industry.
The Return On Equity of CPHI (-59.45%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.88% | ||
| ROE | -59.45% | ||
| ROIC | N/A |
ROA(3y)-18.68%
ROA(5y)-32.54%
ROE(3y)-63.46%
ROE(5y)-90.06%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CPHI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CPHI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CPHI has more shares outstanding
CPHI has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CPHI has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -4.40, we must say that CPHI is in the distress zone and has some risk of bankruptcy.
CPHI has a Altman-Z score of -4.40. This is in the lower half of the industry: CPHI underperforms 61.58% of its industry peers.
CPHI has a debt to FCF ratio of 9.89. This is a negative value and a sign of low solvency as CPHI would need 9.89 years to pay back of all of its debts.
CPHI has a Debt to FCF ratio of 9.89. This is amongst the best in the industry. CPHI outperforms 81.58% of its industry peers.
A Debt/Equity ratio of 0.38 indicates that CPHI is not too dependend on debt financing.
CPHI's Debt to Equity ratio of 0.38 is on the low side compared to the rest of the industry. CPHI is outperformed by 61.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.38 | ||
| Debt/FCF | 9.89 | ||
| Altman-Z | -4.4 |
ROIC/WACCN/A
WACC6.72%
2.3 Liquidity
A Current Ratio of 0.84 indicates that CPHI may have some problems paying its short term obligations.
CPHI has a worse Current ratio (0.84) than 92.11% of its industry peers.
CPHI has a Quick Ratio of 0.84. This is a bad value and indicates that CPHI is not financially healthy enough and could expect problems in meeting its short term obligations.
CPHI's Quick ratio of 0.24 is on the low side compared to the rest of the industry. CPHI is outperformed by 96.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.84 | ||
| Quick Ratio | 0.24 |
3. Growth
3.1 Past
CPHI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.76%, which is quite impressive.
CPHI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -21.36%.
Measured over the past years, CPHI shows a very negative growth in Revenue. The Revenue has been decreasing by -10.68% on average per year.
EPS 1Y (TTM)73.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.27%
Revenue 1Y (TTM)-21.36%
Revenue growth 3Y-13.59%
Revenue growth 5Y-10.68%
Sales Q2Q%-15.76%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
CPHI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, CPHI is valued cheaper than 89.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.32 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
CPHI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CHINA PHARMA HOLDINGS INC
NYSEARCA:CPHI (12/23/2024, 2:06:36 PM)
0.1837
+0.01 (+5.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners0.35%
Inst Owner Change-32.22%
Ins Owners53.69%
Ins Owner Change0%
Market Cap3.54M
Analysts0
Price TargetN/A
Short Float %1.1%
Short Ratio0.3
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.57 | ||
| P/FCF | 12.32 | ||
| P/OCF | 10.81 | ||
| P/B | 0.48 | ||
| P/tB | 1.17 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.62
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.01
FCFY8.12%
OCF(TTM)0.02
OCFY9.25%
SpS0.32
BVpS0.38
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.88% | ||
| ROE | -59.45% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | 4.59% |
ROA(3y)-18.68%
ROA(5y)-32.54%
ROE(3y)-63.46%
ROE(5y)-90.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.38 | ||
| Debt/FCF | 9.89 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.84 | ||
| Quick Ratio | 0.24 | ||
| Altman-Z | -4.4 |
F-Score3
WACC6.72%
ROIC/WACCN/A
Cap/Depr(3y)9.83%
Cap/Depr(5y)13.3%
Cap/Sales(3y)3.22%
Cap/Sales(5y)3.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.27%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-21.36%
Revenue growth 3Y-13.59%
Revenue growth 5Y-10.68%
Sales Q2Q%-15.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-55.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y111.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y117.57%
OCF growth 3YN/A
OCF growth 5YN/A